摘要
目的观察沙美特罗氟替卡松(舒利迭)联合噻托溴胺(思力华)治疗中重度COPD患者的临床疗效。方法将60例中重度COPD稳定期患者随机分成两组,A组:吸入舒利迭(50μg/250μg)2次/d,吸入思力华(18μg)1次/d;B组:吸入舒利迭(50μg/250μg)2次/d,疗程3个月。以两组治疗前后的血气分析、肺功能、6分钟步行试验为观察指标。结果 A组的血气分析、肺功能、6MWT与B组相比较差异有统计学意义(P<0.05)。结论沙美特罗氟替卡松与噻托溴胺联合治疗中重度COPD患者的效果确切,值得推广。
Objective To observe the effects of salmeterol fluticasone （Seretide） combined with tiotropium （Spiriva） in the treatment of patients with chronic obstructive pulmonary disease （COPD） at moderate and severe stages. Methods 60 COPD patients at moderate and severe stages were randomly divided into two groups. The group A received Seretide inhalation 50 μg/230 μg twice a day and Spirlva inhalation 18 μg once a day. The group B received Seretide inhalation 50 μg/250μg twice a day 0nly. The total treatment course was 3 months. The blood gas analysis, lung function, and 6-min walking distance were analyzed before and after treatment between the two groups. Results The differences of blood gas analysis, lung function, 6-minute walking distance between the two groups showed statistical significance （ P 〈 0. 05）. Conclusion Salmeterol fluticasone combined with tiotropium has better curative effect in the treat- ment of COPD patients at moderate and severe stages and it＇s worth to be promoted and applied in clinical practice.
出处
《临床肺科杂志》
2013年第3期457-458,共2页
Journal of Clinical Pulmonary Medicine
关键词
沙美特罗氟替卡松
噻托溴胺
慢性阻塞性肺疾病
肺功能
salmeterol fluticasone
tiotropium
chronic obstructive puhnonary disease
lung function
